Eliz­a­beth War­ren wants Gilead CEO Daniel O'­Day in the hot seat to talk drug pric­ing and com­pet­i­tive­ness

Giv­en Gilead’s ex­pe­ri­ence in de­vel­op­ing sto­ried new drugs for he­pati­tis C and Covid-19, and mar­ket­ing them with hefty price tags, Mass­a­chu­setts Sen. Eliz­a­beth War­ren (D) sent a let­ter on Fri­day to CEO Daniel O’Day, call­ing on him to tes­ti­fy be­fore a sub­com­mit­tee of the Sen­ate Fi­nance Com­mit­tee on “Pro­mot­ing Do­mes­tic Com­pe­ti­tion and In­ter­na­tion­al Com­pet­i­tive­ness.”

While not­ing that “the pro­hib­i­tive­ly high prices of Gilead’s drugs have made it hard for pa­tients to ac­cess the life­sav­ing treat­ments they need, forced tax­pay­ers to bear the brunt of high costs, and in­hib­it­ed com­pe­ti­tion,” War­ren said she’s of­fer­ing O’Day “an op­por­tu­ni­ty to of­fer con­text on phar­ma­ceu­ti­cal com­pe­ti­tion and the bur­den of high drug prices on pa­tients and the Amer­i­can pub­lic.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER